Fertility-preserving treatment outcome in endometrial cancer or atypical hyperplasia patients with polycystic ovary syndrome

Fertility-preserving treatment outcome in endometrial cancer or atypical hyperplasia patients with polycystic ovary syndrome

Objective: This study aimed to investigate the impact of polycystic ovary syndrome (PCOS) on fertility-sparing treatment in young patients with atypical endometrial hyperplasia (AEH) or endometrioid endometrial cancer (EEC). Methods: A total of 285 patients with EEC (n=76, FIGO stage IA, without myo...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of gynecologic oncology 2021, 32(5), , pp.1-14
Hauptverfasser: Wang, Lulu, Luo, Xuezhen, Wang, Qian, Lv, Qiaoying, Wu, Pengfei, Liu, Wei, Chen, Xiaojun
Format: Artikel
Sprache:eng
Schlagworte:
Life Sciences & Biomedicine
Obstetrics & Gynecology
Oncology
Original
Science & Technology
산부인과학
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page e70
container_issue 5
container_start_page e70
container_title Journal of gynecologic oncology
container_volume 32
creator Wang, Lulu
Luo, Xuezhen
Wang, Qian
Lv, Qiaoying
Wu, Pengfei
Liu, Wei
Chen, Xiaojun
description Objective: This study aimed to investigate the impact of polycystic ovary syndrome (PCOS) on fertility-sparing treatment in young patients with atypical endometrial hyperplasia (AEH) or endometrioid endometrial cancer (EEC). Methods: A total of 285 patients with EEC (n=76, FIGO stage IA, without myometrium invasion) or AEH (n=209) who received progestin-based fertility-sparing treatment were evaluated retrospectively. Among the 285 patients, 103 (36.1%), including 70 AEH cases and 33 EEC cases, were diagnosed with PCOS. General characteristics, cumulative 16- and 32-week complete response (CR) rate, pregnancy outcome and recurrence were compared between patients with or without PCOS. Results: The cumulative 16-week CR rate was lower in the PCOS group than in the non-PCOS group (18.4% vs. 33.8%, p=0.006). Patients with PCOS took longer treatment duration to achieve CR (7.0 months vs. 5.4 months, p=0.006) and shorter time to relapse after CR (9.6 months vs. 17.6 months, p=0.040) compared with non-PCOS group. After adjusting for patient age, body mass index, PCOS, homeostasis model assessment-insulin resistance index, and serum testosterone levels, we found that body mass index >= 25 kg/m(2) (HR=0.583; 95% CI=0.365-0.932; p=0.024) and PCOS (HR=0.545; 95% CI=0.324-0.917; p=0.022) were significantly correlated with lower 16-week CR rate. Conclusion: PCOS was associated with lower 16-week CR rate, longer treatment duration and shorter recurrence interval in patients with AEH or EEC receiving fertility-preserving treatment.
doi_str_mv 10.3802/jgo.2021.32.e70
format Article
fullrecord <record><control><sourceid>proquest_webof</sourceid><recordid>TN_cdi_webofscience_primary_000684595200003</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2541782612</sourcerecordid><originalsourceid>FETCH-LOGICAL-c404t-d54e77ecc09a4476f33224ccb4d1293e32963e795bccb9d5706b6e83b7306c033</originalsourceid><addsrcrecordid>eNqNkc1r3DAQxU1paT7ac686thRvZEm2pEshLEkTCBRKehayPN5VYkuuJG8w9I-vdjcs9NbTDKP3njT6FcWnCq-owOTqaeNXBJNqRckKOH5TnBOM6xJTKd-eeoHPiosYnzBuOBbkfXFGWUUJbuR58ecWQrKDTUs5BYgQdtZtUAqg0wguIT8n40dA1iFwXe5SsHpARjsDAfmAdFoma_Jou0wQpkFHq9Gkk83uiF5s2qLJD4tZYrIG-Z0OC4qL60LO-lC86_UQ4eNrvSx-3d48ru_Khx_f79fXD6VhmKWyqxlwDsZgqRnjTU8pIcyYlnUVkRQokQ0FLus2z2RXc9y0DQjacoobgym9LL4cc13o1bOxymt7qBuvnoO6_vl4r6SopeQka78dtdPcjtCZvEbQg5qCHfPTD85_T5zd5pydErQhotoHfH4NCP73DDGp0UYDw6Ad-DkqUrOKC9IcpFdHqQk-xgD96ZoKqz1flfmqPV9Ficp8s-Pr0fECre-jyb9s4OTCmbBgtawzeHzYW_y_em1Tpubd2s8u0b_K97y1</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2541782612</pqid></control><display><type>article</type><title>Fertility-preserving treatment outcome in endometrial cancer or atypical hyperplasia patients with polycystic ovary syndrome</title><source>KoreaMed Synapse</source><source>DOAJ Directory of Open Access Journals</source><source>KoreaMed Open Access</source><source>Web of Science - Science Citation Index Expanded - 2021&lt;img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /&gt;</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Wang, Lulu ; Luo, Xuezhen ; Wang, Qian ; Lv, Qiaoying ; Wu, Pengfei ; Liu, Wei ; Chen, Xiaojun</creator><creatorcontrib>Wang, Lulu ; Luo, Xuezhen ; Wang, Qian ; Lv, Qiaoying ; Wu, Pengfei ; Liu, Wei ; Chen, Xiaojun</creatorcontrib><description>Objective: This study aimed to investigate the impact of polycystic ovary syndrome (PCOS) on fertility-sparing treatment in young patients with atypical endometrial hyperplasia (AEH) or endometrioid endometrial cancer (EEC). Methods: A total of 285 patients with EEC (n=76, FIGO stage IA, without myometrium invasion) or AEH (n=209) who received progestin-based fertility-sparing treatment were evaluated retrospectively. Among the 285 patients, 103 (36.1%), including 70 AEH cases and 33 EEC cases, were diagnosed with PCOS. General characteristics, cumulative 16- and 32-week complete response (CR) rate, pregnancy outcome and recurrence were compared between patients with or without PCOS. Results: The cumulative 16-week CR rate was lower in the PCOS group than in the non-PCOS group (18.4% vs. 33.8%, p=0.006). Patients with PCOS took longer treatment duration to achieve CR (7.0 months vs. 5.4 months, p=0.006) and shorter time to relapse after CR (9.6 months vs. 17.6 months, p=0.040) compared with non-PCOS group. After adjusting for patient age, body mass index, PCOS, homeostasis model assessment-insulin resistance index, and serum testosterone levels, we found that body mass index &gt;= 25 kg/m(2) (HR=0.583; 95% CI=0.365-0.932; p=0.024) and PCOS (HR=0.545; 95% CI=0.324-0.917; p=0.022) were significantly correlated with lower 16-week CR rate. Conclusion: PCOS was associated with lower 16-week CR rate, longer treatment duration and shorter recurrence interval in patients with AEH or EEC receiving fertility-preserving treatment.</description><identifier>ISSN: 2005-0380</identifier><identifier>EISSN: 2005-0399</identifier><identifier>DOI: 10.3802/jgo.2021.32.e70</identifier><identifier>PMID: 34132069</identifier><language>eng</language><publisher>SEOUL: Korean Soc Gynecology Oncology &amp; Colposcopy</publisher><subject>Life Sciences &amp; Biomedicine ; Obstetrics &amp; Gynecology ; Oncology ; Original ; Science &amp; Technology ; 산부인과학</subject><ispartof>Journal of Gynecologic Oncology, 2021, 32(5), , pp.1-14</ispartof><rights>Copyright © 2021. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology 2021 Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>13</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000684595200003</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c404t-d54e77ecc09a4476f33224ccb4d1293e32963e795bccb9d5706b6e83b7306c033</citedby><cites>FETCH-LOGICAL-c404t-d54e77ecc09a4476f33224ccb4d1293e32963e795bccb9d5706b6e83b7306c033</cites><orcidid>0000-0002-8892-5774 ; 0000-0002-1253-3344 ; 0000-0002-5493-1500 ; 0000-0003-3610-2538 ; 0000-0001-6781-7304 ; 0000-0003-0516-8067 ; 0000-0001-7507-4141</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8362812/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8362812/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,728,781,785,865,886,2115,27929,27930,39263,53796,53798</link.rule.ids><backlink>$$Uhttps://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002753734$$DAccess content in National Research Foundation of Korea (NRF)$$Hfree_for_read</backlink></links><search><creatorcontrib>Wang, Lulu</creatorcontrib><creatorcontrib>Luo, Xuezhen</creatorcontrib><creatorcontrib>Wang, Qian</creatorcontrib><creatorcontrib>Lv, Qiaoying</creatorcontrib><creatorcontrib>Wu, Pengfei</creatorcontrib><creatorcontrib>Liu, Wei</creatorcontrib><creatorcontrib>Chen, Xiaojun</creatorcontrib><title>Fertility-preserving treatment outcome in endometrial cancer or atypical hyperplasia patients with polycystic ovary syndrome</title><title>Journal of gynecologic oncology</title><addtitle>J GYNECOL ONCOL</addtitle><description>Objective: This study aimed to investigate the impact of polycystic ovary syndrome (PCOS) on fertility-sparing treatment in young patients with atypical endometrial hyperplasia (AEH) or endometrioid endometrial cancer (EEC). Methods: A total of 285 patients with EEC (n=76, FIGO stage IA, without myometrium invasion) or AEH (n=209) who received progestin-based fertility-sparing treatment were evaluated retrospectively. Among the 285 patients, 103 (36.1%), including 70 AEH cases and 33 EEC cases, were diagnosed with PCOS. General characteristics, cumulative 16- and 32-week complete response (CR) rate, pregnancy outcome and recurrence were compared between patients with or without PCOS. Results: The cumulative 16-week CR rate was lower in the PCOS group than in the non-PCOS group (18.4% vs. 33.8%, p=0.006). Patients with PCOS took longer treatment duration to achieve CR (7.0 months vs. 5.4 months, p=0.006) and shorter time to relapse after CR (9.6 months vs. 17.6 months, p=0.040) compared with non-PCOS group. After adjusting for patient age, body mass index, PCOS, homeostasis model assessment-insulin resistance index, and serum testosterone levels, we found that body mass index &gt;= 25 kg/m(2) (HR=0.583; 95% CI=0.365-0.932; p=0.024) and PCOS (HR=0.545; 95% CI=0.324-0.917; p=0.022) were significantly correlated with lower 16-week CR rate. Conclusion: PCOS was associated with lower 16-week CR rate, longer treatment duration and shorter recurrence interval in patients with AEH or EEC receiving fertility-preserving treatment.</description><subject>Life Sciences &amp; Biomedicine</subject><subject>Obstetrics &amp; Gynecology</subject><subject>Oncology</subject><subject>Original</subject><subject>Science &amp; Technology</subject><subject>산부인과학</subject><issn>2005-0380</issn><issn>2005-0399</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>HGBXW</sourceid><recordid>eNqNkc1r3DAQxU1paT7ac686thRvZEm2pEshLEkTCBRKehayPN5VYkuuJG8w9I-vdjcs9NbTDKP3njT6FcWnCq-owOTqaeNXBJNqRckKOH5TnBOM6xJTKd-eeoHPiosYnzBuOBbkfXFGWUUJbuR58ecWQrKDTUs5BYgQdtZtUAqg0wguIT8n40dA1iFwXe5SsHpARjsDAfmAdFoma_Jou0wQpkFHq9Gkk83uiF5s2qLJD4tZYrIG-Z0OC4qL60LO-lC86_UQ4eNrvSx-3d48ru_Khx_f79fXD6VhmKWyqxlwDsZgqRnjTU8pIcyYlnUVkRQokQ0FLus2z2RXc9y0DQjacoobgym9LL4cc13o1bOxymt7qBuvnoO6_vl4r6SopeQka78dtdPcjtCZvEbQg5qCHfPTD85_T5zd5pydErQhotoHfH4NCP73DDGp0UYDw6Ad-DkqUrOKC9IcpFdHqQk-xgD96ZoKqz1flfmqPV9Ficp8s-Pr0fECre-jyb9s4OTCmbBgtawzeHzYW_y_em1Tpubd2s8u0b_K97y1</recordid><startdate>20210901</startdate><enddate>20210901</enddate><creator>Wang, Lulu</creator><creator>Luo, Xuezhen</creator><creator>Wang, Qian</creator><creator>Lv, Qiaoying</creator><creator>Wu, Pengfei</creator><creator>Liu, Wei</creator><creator>Chen, Xiaojun</creator><general>Korean Soc Gynecology Oncology &amp; Colposcopy</general><general>Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology; Japan Society of Gynecologic Oncology</general><general>대한부인종양학회</general><scope>BLEPL</scope><scope>DTL</scope><scope>HGBXW</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>ACYCR</scope><orcidid>https://orcid.org/0000-0002-8892-5774</orcidid><orcidid>https://orcid.org/0000-0002-1253-3344</orcidid><orcidid>https://orcid.org/0000-0002-5493-1500</orcidid><orcidid>https://orcid.org/0000-0003-3610-2538</orcidid><orcidid>https://orcid.org/0000-0001-6781-7304</orcidid><orcidid>https://orcid.org/0000-0003-0516-8067</orcidid><orcidid>https://orcid.org/0000-0001-7507-4141</orcidid></search><sort><creationdate>20210901</creationdate><title>Fertility-preserving treatment outcome in endometrial cancer or atypical hyperplasia patients with polycystic ovary syndrome</title><author>Wang, Lulu ; Luo, Xuezhen ; Wang, Qian ; Lv, Qiaoying ; Wu, Pengfei ; Liu, Wei ; Chen, Xiaojun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c404t-d54e77ecc09a4476f33224ccb4d1293e32963e795bccb9d5706b6e83b7306c033</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Life Sciences &amp; Biomedicine</topic><topic>Obstetrics &amp; Gynecology</topic><topic>Oncology</topic><topic>Original</topic><topic>Science &amp; Technology</topic><topic>산부인과학</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Lulu</creatorcontrib><creatorcontrib>Luo, Xuezhen</creatorcontrib><creatorcontrib>Wang, Qian</creatorcontrib><creatorcontrib>Lv, Qiaoying</creatorcontrib><creatorcontrib>Wu, Pengfei</creatorcontrib><creatorcontrib>Liu, Wei</creatorcontrib><creatorcontrib>Chen, Xiaojun</creatorcontrib><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>Web of Science - Science Citation Index Expanded - 2021</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Korean Citation Index</collection><jtitle>Journal of gynecologic oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Lulu</au><au>Luo, Xuezhen</au><au>Wang, Qian</au><au>Lv, Qiaoying</au><au>Wu, Pengfei</au><au>Liu, Wei</au><au>Chen, Xiaojun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Fertility-preserving treatment outcome in endometrial cancer or atypical hyperplasia patients with polycystic ovary syndrome</atitle><jtitle>Journal of gynecologic oncology</jtitle><stitle>J GYNECOL ONCOL</stitle><date>2021-09-01</date><risdate>2021</risdate><volume>32</volume><issue>5</issue><spage>e70</spage><epage>e70</epage><pages>e70-e70</pages><artnum>70</artnum><issn>2005-0380</issn><eissn>2005-0399</eissn><abstract>Objective: This study aimed to investigate the impact of polycystic ovary syndrome (PCOS) on fertility-sparing treatment in young patients with atypical endometrial hyperplasia (AEH) or endometrioid endometrial cancer (EEC). Methods: A total of 285 patients with EEC (n=76, FIGO stage IA, without myometrium invasion) or AEH (n=209) who received progestin-based fertility-sparing treatment were evaluated retrospectively. Among the 285 patients, 103 (36.1%), including 70 AEH cases and 33 EEC cases, were diagnosed with PCOS. General characteristics, cumulative 16- and 32-week complete response (CR) rate, pregnancy outcome and recurrence were compared between patients with or without PCOS. Results: The cumulative 16-week CR rate was lower in the PCOS group than in the non-PCOS group (18.4% vs. 33.8%, p=0.006). Patients with PCOS took longer treatment duration to achieve CR (7.0 months vs. 5.4 months, p=0.006) and shorter time to relapse after CR (9.6 months vs. 17.6 months, p=0.040) compared with non-PCOS group. After adjusting for patient age, body mass index, PCOS, homeostasis model assessment-insulin resistance index, and serum testosterone levels, we found that body mass index &gt;= 25 kg/m(2) (HR=0.583; 95% CI=0.365-0.932; p=0.024) and PCOS (HR=0.545; 95% CI=0.324-0.917; p=0.022) were significantly correlated with lower 16-week CR rate. Conclusion: PCOS was associated with lower 16-week CR rate, longer treatment duration and shorter recurrence interval in patients with AEH or EEC receiving fertility-preserving treatment.</abstract><cop>SEOUL</cop><pub>Korean Soc Gynecology Oncology &amp; Colposcopy</pub><pmid>34132069</pmid><doi>10.3802/jgo.2021.32.e70</doi><tpages>14</tpages><orcidid>https://orcid.org/0000-0002-8892-5774</orcidid><orcidid>https://orcid.org/0000-0002-1253-3344</orcidid><orcidid>https://orcid.org/0000-0002-5493-1500</orcidid><orcidid>https://orcid.org/0000-0003-3610-2538</orcidid><orcidid>https://orcid.org/0000-0001-6781-7304</orcidid><orcidid>https://orcid.org/0000-0003-0516-8067</orcidid><orcidid>https://orcid.org/0000-0001-7507-4141</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2005-0380
ispartof Journal of Gynecologic Oncology, 2021, 32(5), , pp.1-14
issn 2005-0380
2005-0399
language eng
recordid cdi_webofscience_primary_000684595200003
source KoreaMed Synapse; DOAJ Directory of Open Access Journals; KoreaMed Open Access; Web of Science - Science Citation Index Expanded - 2021<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" />; EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Life Sciences & Biomedicine
Obstetrics & Gynecology
Oncology
Original
Science & Technology
산부인과학
title Fertility-preserving treatment outcome in endometrial cancer or atypical hyperplasia patients with polycystic ovary syndrome
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-11T12%3A42%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_webof&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Fertility-preserving%20treatment%20outcome%20in%20endometrial%20cancer%20or%20atypical%20hyperplasia%20patients%20with%20polycystic%20ovary%20syndrome&rft.jtitle=Journal%20of%20gynecologic%20oncology&rft.au=Wang,%20Lulu&rft.date=2021-09-01&rft.volume=32&rft.issue=5&rft.spage=e70&rft.epage=e70&rft.pages=e70-e70&rft.artnum=70&rft.issn=2005-0380&rft.eissn=2005-0399&rft_id=info:doi/10.3802/jgo.2021.32.e70&rft_dat=%3Cproquest_webof%3E2541782612%3C/proquest_webof%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2541782612&rft_id=info:pmid/34132069&rfr_iscdi=true